News about "Pebrilzo"

Biocon Receives US FDA Approval for Pertuzumab Biosimilar Pebrilzo

Biocon Receives US FDA Approval for Pertuzumab Biosimilar Pebrilzo

Biocon receives US FDA approval for Pebrilzo (pertuzumab-qcay), a biosimilar of Perjeta, for HER2-positive breast cancer, marking its fifth FDA-approved oncology biosimilar.

PEBRILZO | 16/11/2026 | By News Bureau


 

 

We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.

More information: Privacy Policy

 pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members